Using pregabalin and lofexidine to help treat opioid withdrawal in outpatients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial evaluates the effectiveness and safety of combining lofexidine with pregabalin compared to a placebo in managing opioid withdrawal symptoms in outpatient settings. Participants, who are adults with opioid use disorder interested in extended-release injectable naltrexone, will be randomized to receive either the active treatment or placebo. The study aims to determine if this combination can improve withdrawal management and facilitate a smoother transition to naltrexone treatment. The trial builds on previous inpatient findings that suggested the combination was more effective than placebo in reducing withdrawal symptoms.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male and/or female subjects ≥ 18 years of age
2. Meet DSM-5 criteria for an Opioid Use Disorder with physiologic features. Have met 2 or more of the 11 criteria for an OUD including tolerance and withdrawal within the last 12 months
3. Interested in opioid antagonist treatment
4. Used opioids in 20 or more of the last 30 days
5. A stable address in the local area; not planning to move in the next 60 days.
6. Have documents for ID check
7. Absence of medical or psychiatric conditions that are likely to interfere with study participation
8. Has 12 lead ECG demonstrating a QTc ≤450 msec and a QRS ≤120 msec. Site PI has final determination for study inclusion if readings exceed these limits. The PENN cardiologists and medical monitor are available for consultation when needed
9. Negative pregnancy test and using adequate contraception if of childbearing potential.

Exclusion Criteria:

1. Current psychotic disorder (bipolar I, schizophrenia, major depression that is not in remission
2. Alcohol, benzodiazepine, or other sedative use disorder with physiological features that require medication for detoxification
3. Allergy or other serious adverse event due to treatment with pregabalin, XR-NTX, or lofexidine
4. Pending incarceration or plans to leave the immediate area in the next 30 days
5. Homicidal or otherwise behaviorally disturbed requiring immediate attention
6. High risk for suicide as determined by answering 'yes' to questions 4 and/or 5 on C-SSRS
7. Blood pressure \<90 mm Hg (systolic) or \<60 mm Hg (diastolic). If value out of normal range, the investigator and study Clinician will decide subject inclusion/exclusion on case-by-case basis
8. Heart rate and/or pulse\<50 bpm at screening-sitting
9. An Estimated Glomerular Filtration Rate eGFR\<70 mL/min/1.73m2
10. A History of, or current Seizure disorder (excluding childhood febrile seizures)
11. Inability to read and/or understand English. For example, unable to understand the informed consent as demonstrated by failing to answer 9/10 questions correctly on the quiz
12. 12\. Pregnant or breastfeeding
13. 13\. Currently taking sympathomimetic drugs, or a thiazolidinedione antidiabetic
14. ALT and/or AST \>4X upper limit of normal
15. A Child-Pugh score \>7
16. Currently receiving opioids for pain management
17. In a treatment study where medication was administered in the last 30 days
18. Currently using medications that are known to be strong or moderate inhibitors of CYP2D6 such as fluoxetine, paroxetine, mirabegron, bupropion, quinidine, terbinafine, cimetidine, cinacalcet, duloxetine, or fluvoxamine
19. In a methadone maintenance or buprenorphine treatment program within the last 30 days

Where it's running

• University of Pennsylvania, Treatment Research Center
  Philadelphia, Pennsylvania, United States Recruiting
• Mountain Manor Treatment Center
  Baltimore, Maryland, United States Not yet recruiting

Study contacts

• Study coordinator: Kyle M Kampman, MD
• Email: Kampman@pennmedicine.upenn.edu
• Phone: 215-746-2764

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Serratus vs Erector Spinae Block for Pain After Unilateral Breast Surgery

  This trial tests whether serratus posterior superior intercostal plane block or erector spinae plane block reduces chronic pain 3 months after unilateral breast surgery in adult women.

  Recruiting Kocaeli City Hospital · İzmit, Kocaeli · NCT07674836

• Using mHealth to Help Black Adults in the Midwest With Opioid/Stimulant Use and Mood Symptoms

  This study tests a mobile health program to support recovery and mood in Black adults who use opioids or stimulants and are seeking treatment.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT07673380

• Targeting alcohol-opioid co-use among young adults with a new mobile health tool

  A mobile health app is being tested to help young adults reduce drinking and opioid use when they occur together.

  Recruiting Brown University · Providence, Rhode Island · NCT07663448

• Dexa vs Dexmedetomidine with Bupivacaine in TAP Block for Laparotomy Analgesia

  This study tests whether adding dexamethasone or dexmedetomidine to bupivacaine in a TAP block improves postoperative pain control after laparotomy.

  Recruiting Phase 2/3 Sahiwal medical college sahiwal · Sahiwal, Punjab Province · NCT07590752

• Stress response with desflurane versus opioid-free TIVA during weight-loss surgery

  This study will test whether adding the inhaled anesthetic desflurane to opioid-free anesthesia changes the body's perioperative stress response in people having bariatric (weight-loss) surgery.

  Recruiting G.Gennimatas General Hospital · Athens · NCT07568938

• Erector Spinae Block vs Paravertebral Block for Chronic Pain After Mastectomy

  This trial tests whether an erector spinae block can better prevent chronic pain after mastectomy than a paravertebral block in adults 18–80.

  Recruiting American University of Beirut Medical Center · Beirut · NCT07561411

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.